News
08 April 2020
Asthma , COPD
INFORM, - Patient Evidence, - Research Projects

If you are an asthma or COPD patient and do not properly respond to your treatments, the 3TR project might be interesting for you:

With 3TR – taxonomy, treatment, target and remission - researchers are trying to identify biomarker signatures and molecular mechanisms improving our understanding of the underlying biology behind seven different immune-mediated, allergic and inflammatory diseases, including asthma and COPD.

The information gained from the project will extend our knowledge of why symptoms improve with certain treatments for some patients, but do not do so for others. This will lead to improved asthma and COPD management and personalised therapy. Further, it will allow being able to better predict whether a patient will benefit from a particular treatment or not.

EFA community brings in the patient perspective

EFA’s role in 3TR is to provide the patients’ perspective. Therefore, together with the European Lung Foundation (ELF), we have recently set up a Patient Respiratory Group.

The group is currently composed of 16 asthma and COPD patients. They will provide advice and ensure that patients are at the centre of the project’s activities, such as data collection and the design of clinical research and dissemination. 

The 3TR project was launched in November 2019 and is funded by the Innovative Medicine Initiative (IMI), a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA) which provides funding for health research and innovation.

More information about the 3TR project can be found here.

Dear Visitor,

for regularly updated information on Covid-19 for allergy and respiratory patients, please consult our Covid-19 resource and information hub.
Stay safe!
The EFA Team